

# Quarterly Industry Update

As of June 30, 2014

Industry: Medical Device



## Industry Summary

Cogent Valuation identified publicly traded companies, IPOs, and recent M&A transactions within the Medical Device industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Since June 30, 2013, the median 52-week share price return of the Medical Device industry has increased by 39.5%. In the last quarter, the median price-to-earnings multiple decreased from 25.6x to 21.8x.

## Comparable Public Company Key Statistics


Median 52-Week Return	39.5%	Median EV/Revenue Multiple	3.6x	Median Price/Earnings Multiple	21.8x
Median 3-Year CAGR Return	14.5%	Median EV/EBITDA Multiple	12.8x	Median EV/Gross CF Multiple	20.0x

## Comparable Public Company Market Price Returns (As of June 30, 2014)


	YTD	3 Month	1 Year	2 Year	3 Year	5 Year	2012	2011	2010	2009	2008
Medtronic plc	55.4%	3.6%	23.9%	28.3%	18.3%	12.8%	7.2%	3.1%	-15.7%	40.0%	-37.5%
Boston Scientific Corporation	122.9%	-5.5%	37.8%	50.1%	22.7%	4.7%	7.3%	-29.5%	-15.9%	16.3%	-33.4%
St. Jude Medical Inc.	91.6%	5.9%	51.8%	31.7%	13.2%	11.0%	5.4%	-19.8%	16.2%	11.6%	-18.9%
CR Bard Inc.	46.3%	-3.4%	31.6%	15.4%	9.2%	13.9%	14.3%	-6.8%	17.8%	-7.5%	-11.1%
Edwards Lifesciences Corp.	-4.8%	15.7%	27.7%	-8.8%	-0.5%	20.3%	27.5%	-12.5%	86.2%	58.1%	19.5%
CONMED Corporation	58.0%	1.6%	41.3%	26.3%	15.7%	23.3%	8.9%	-2.9%	15.9%	-4.8%	3.6%
Greatbatch, Inc.	111.1%	6.8%	49.6%	47.0%	22.3%	16.8%	5.2%	-8.5%	25.6%	-27.3%	32.4%
Thoratec Corp.	-7.1%	-2.7%	11.3%	1.9%	2.0%	5.4%	11.8%	18.5%	5.2%	-17.1%	78.6%
CryoLife Inc.	43.7%	-10.1%	43.0%	30.8%	16.9%	10.1%	29.8%	-11.4%	-15.6%	-33.9%	22.1%
ABIOMED, Inc.	87.1%	-3.5%	16.6%	5.0%	15.8%	23.3%	-27.2%	92.2%	10.1%	-46.8%	5.7%
Cardiovascular Systems Inc.	148.3%	-2.0%	47.0%	78.4%	28.9%	32.2%	27.4%	-15.5%	154.0%	N/A	N/A
Heartware International Inc.	5.4%	-5.6%	-6.9%	-0.2%	6.1%	26.0%	21.7%	-21.2%	146.9%	N/A	N/A
AtriCure, Inc.	166.4%	-2.3%	93.5%	38.3%	12.5%	39.3%	-37.8%	8.1%	70.0%	172.1%	-83.1%
Stereotaxis Inc.	39.2%	-16.5%	129.0%	30.0%	-53.4%	-38.0%	-69.0%	-78.5%	-2.5%	-10.7%	-64.0%
<b>Median of Industry Public Companies</b>	<b>56.7%</b>	<b>-2.5%</b>	<b>39.5%</b>	<b>29.2%</b>	<b>14.5%</b>	<b>15.4%</b>	<b>8.1%</b>	<b>-10.0%</b>	<b>16.1%</b>	<b>-6.2%</b>	<b>-3.8%</b>

(Multiple year periods are calculated as the average annual return.)

## Median Quarterly Revenue Growth of All Medical Device Companies



## Median Gross Profit, EBITDA, Net Income and Gross Cash Flow Margins



## Median Public Company Multiples of the Medical Device Industry

Date:	6/30/2012	9/30/2012	12/31/2012	3/31/2013	6/30/2013	9/30/2013	12/31/2013	3/31/2014	6/30/2014
EV/Revenues Multiple	2.4x	2.6x	2.5x	2.7x	3.0x	3.2x	3.5x	3.6x	3.6x
EV/EBITDA Multiple	7.8x	9.6x	8.9x	9.2x	9.3x	10.3x	12.5x	13.4x	12.8x
Price/Earnings Multiple	21.1x	23.8x	20.6x	20.6x	22.0x	23.6x	21.9x	25.6x	21.8x
EV/Gross Cash Flows Multiple	15.8x	18.2x	15.8x	19.2x	19.5x	20.5x	21.3x	21.6x	20.0x

This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for additional information or questions in connection with this research report.

# Quarterly Industry Update

As of June 30, 2014

Industry: Medical Device


## Industry Initial Public Offerings (dollars in millions, except share prices)

Offer Date	Company Name	Offer Price	Shares Offered	Amount Raised	Total Assets	Debt	LTM Revenues	LTM EBITDA	LTM Net Income	LTM Cash Flows
11/17/2011	Sphere Medical Holding PLC	\$1.46	15.1	\$22.1	\$19.4	\$0.0	\$0.0	(\$7.0)	(\$8.1)	(\$6.7)
4/18/2011	InspireMD, Inc.	\$1.50	7.0	\$10.4	\$12.7	\$1.5	\$4.5	(\$3.3)	(\$4.6)	(\$3.2)
10/22/2010	STENTYS Société anonyme	\$16.70	1.9	\$31.6	\$34.7	\$1.7	\$0.3	(\$9.4)	(\$9.8)	(\$9.1)
7/7/2010	Carmat Société Anonyme	\$23.67	0.8	\$19.6	\$8.7	\$0.0	\$4.4	\$0.0	(\$4.3)	\$0.3
12/12/2005	Lombard Medical Technologies Limited	\$2.82	14.4	\$47.0	\$11.8	\$7.4	\$0.1	(\$9.0)	(\$13.0)	(\$8.6)
8/5/2005	AtriCure, Inc.	\$12.00	4.0	\$48.0	\$12.5	\$0.0	\$25.5	(\$5.8)	(\$10.9)	(\$4.7)
1/27/2005	Heartware International Inc.	\$0.39	60.0	\$23.3	N/A	N/A	N/A	N/A	N/A	N/A
8/11/2004	Stereotaxis Inc.	\$8.00	5.0	\$44.0	\$41.1	\$6.0	\$9.9	(\$29.8)	(\$30.5)	(\$29.2)
<b>Median of All IPOs</b>		<b>nm</b>	<b>nm</b>	<b>\$27.4</b>	<b>\$12.7</b>	<b>\$1.5</b>	<b>\$4.4</b>	<b>(\$7.0)</b>	<b>(\$9.8)</b>	<b>(\$6.7)</b>

## Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

Transaction Date	Target	Acquirer	Transaction Size	% Bought
1/8/2014	Grikin Advanced Materials	GRINM Semiconductor	\$33.9	96%
12/31/2013	Endoscopic Technologies, Inc.	AtriCure, Inc.	\$60.7	100%
6/30/2013	Terumo Heart, Inc.	Thoratec Corp.	\$56.5	100%
12/19/2012	Thomas Medical Products	Merit Medical Systems, Inc.	\$167.0	100%
11/30/2012	Defibtech, LLC	Resuscitation Solution, Inc.	\$49.0	100%
11/19/2012	Vessix Vascular, Inc.	Boston Scientific Corporation	\$425.0	100%
10/29/2012	Neovasc Medical Ltd., XenoSure	LeMaitre Vascular, Inc.	\$4.6	100%
10/9/2012	Rhythmia Medical, Inc.	Boston Scientific Corporation	\$265.0	100%
10/4/2012	BridgePoint Medical, Inc.	Boston Scientific Corporation	\$110.0	100%
8/16/2012	St. Jude Medical, Inc.	Vascular Solutions Inc.	\$3.0	100%
6/18/2012	Kensey Nash Corporation	Koninklijke DSM N.V.	\$393.3	100%
5/16/2012	Hemosphere, Inc.	CryoLife Inc.	\$21.7	100%
12/16/2011	Lutonix Inc.	CR Bard Inc.	\$328.0	100%
7/18/2011	Estech, Cannulae Product Line	Sorin SpA	\$5.0	100%
5/17/2011	Cardiogenesis Corporation	CryoLife Inc.	\$21.5	100%
<b>Median of All Transaction Targets</b>			<b>\$56.5</b>	<b>100%</b>

## Size of Merger and Acquisition Transactions (dollars in millions)



**Disclosures and Limitations:** This research report is for informational and discussion purposes only. This report and any information presented herein is not investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources Cogent Valuation believes to be reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the content of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the composite used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The content of this report may be used, in part, as a basis for any work that Cogent Valuation performs for you in the future at the sole discretion of Cogent Valuation. THIS REPORT IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE. This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for additional information or questions in connection with this research report. Copyright © 2014 Cogent Valuation. All Rights Reserved. Copyright © 2014 Cogent Valuation. All Rights Reserved.